Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

Clinical trial NCT05810142 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05810142
Sponsor: RenJi Hospital
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Third-line Treatment Dvanced Duodenal Adenocarcinoma Furquinelone Combined With Sintilimab

Start date: 2023-07-01
Primary completion: 2025-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.